Showing results (111-120 of 145) with videos related to
Sort By:
Pageof 15
Annals of Clinical and Translational Neurology|July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluidMolly Reynolds, Irene Tan, Kristy Nguyen, et al.Brain : a Journal of Neurology|April 28, 2012
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesisChristian G Bien, Angela Vincent, Michael H Barnett, et al.Frontiers in Immunology|February 24, 2022
Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple SclerosisJennifer Massey, Katherine Jackson, Mandeep Singh, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 30, 2024
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated diseaseGanesha Liyanage, Benjamin P Trewin, Joseph A Lopez, et al.The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 27, 2024
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.Pageof 15